Key Takeaways TECH struck a deal with USP to distribute mAb and AAV standards, alongside its Maurice analytics platform. TECH aims to ease analytical challenges in mAb and gene therapy development through this partnership. TECH's tools enable efficient, integrated analysis of complex biologics from development to product release.Bio-Techne Corp. (TECH) has recently entered into a distribution agreement with the U.S. Pharmacopeia (“USP”) to sell USP monoclonal antibody (mAb) and recombinant adeno-associate ...

Addressing quality challenges is essential to ensure the safety and quality of biotherapeutics. Both USP and Bio-Techne have a long history of developing solutions to support mAbs and are applying their know-how to solving analytical challenges in AAV-based gene therapies. The ability to purchase USP reference standards from Bio-Techne further simplifies the method development process, enabling customers to assess system suitability and other critical criteria for charge and size based analytical assays on ...